February 6, 2020 / 10:42 PM / 14 days ago

BRIEF-Aduro Biotech Announces Milestone Achieved Under Merck Collaboration For Initiation Of Phase 2 Trial Of Anti-Cd27 Agonist Mk-5890 In Non-Small Cell Lung Cancer

Feb 6 (Reuters) - Aduro Biotech Inc:

* ADURO BIOTECH ANNOUNCES MILESTONE ACHIEVED UNDER MERCK COLLABORATION FOR INITIATION OF PHASE 2 TRIAL OF ANTI-CD27 AGONIST MK-5890 IN NON-SMALL CELL LUNG CANCER

* ADURO BIOTECH- EARNED $10 MILLION DEVELOPMENT MILESTONE PAYMENT UNDER WORLDWIDE LICENSING DEAL WITH MERCK FOR PHASE 2 CLINICAL TRIAL OF MK-5890 INITIATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below